Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01175
|
|||||
| Drug Name |
Didanosine
|
|||||
| Synonyms |
69655-05-6; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; BMY 40900; BMY-40900; CHEBI:490877; DDI; DIDEOXYINOSINE; DRG-0016; DSSTox_CID_2927; Didanosina; Didanosina [INN-Spanish]; Didanosinum; Didanosinum [INN-Latin]; Inosine, 2',3'-dideoxy-; K3GDH6OH08; NCGC00090691-03; NCGC00159514-02; NSC 612049; UNII-K3GDH6OH08; Videx; Videx EC; ddIno; didanosine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11:1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H12N4O3
|
|||||
| Canonical SMILES |
C1CC(OC1CO)N2C=NC3=C2N=CNC3=O
|
|||||
| InChI |
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
|
|||||
| InChIKey |
BXZVVICBKDXVGW-NKWVEPMBSA-N
|
|||||
| CAS Number |
CAS 69655-05-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 236.23 | Topological Polar Surface Area | 88.7 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-1.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103529091
,12014245
,14847321
,15121787
,15121788
,15196316
,17389541
,22431600
,25819905
,26719672
,26754510
,26757698
,29215491
,34715128
,46386730
,46506255
,46508438
,48415887
,48422196
,48422428
,48423223
,48424479
,49681777
,49718183
,56463354
,57313303
,58717761
,595889
,596438
,596681
,597344
,601538
,602978
,622273
,77794640
,7847362
,7885163
,7979070
,7979071
,81093234
,833736
,87351572
,87559876
,90451743
,91612512
,9168
,92308421
,92308956
,92711314
,92729668
|
|||||
| ChEBI ID |
CHEBI:490877
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CNT2 | Transporter Info | Concentrative nucleoside transporter 2 | Substrate | [2] | |
| References | ||||||
| 1 | Didanosine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.